Clinical Trial Update: Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Iressa (gefitinib) as first-line therapy in chemonaive patients with inoperable non-small cell lung cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED